TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01722331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildrakizumab 200 mg
Description: Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Description: Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildrakizumab 100 mg
Description: Tildrakizumab 100 mg/mL PFS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Description: Tildrakizumab 100 mg/mL PFS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo to tildrakizumab PFS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching placebo to tildrakizumab PFS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching placebo to tildrakizumab PFS
Study: NCT01621360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic hip surgery
Description: Hip arthroscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
Study: NCT03556761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral furosemide
Description: Furosemide (Lasix), 20 milligram, PO, PO, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo, PO, daily
Study: NCT03876041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solumedrol
Description: intravenous solution for injection
Study: NCT03759262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
Study: NCT01256398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood autologous or allogeneic HCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01304953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group P+P
Description: In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group P+T
Description: In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
Study: NCT03876041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: intravenous solution for injection
Study: NCT00721526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disulfiram plus lorazepam
Description: Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
Study: NCT02894645

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Intravenous
Study: NCT01493609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Click-East app
Description: Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
Study: NCT02282449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Injectable Port (AngioDynamics Smart Port CT Mini)
Description: The subjects will all receive power injectable port.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Power Injectable Port (Cook Vital Mini Port)
Description: The subjects will all receive non-power injectable port.
Study: NCT03390452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Messaging
Description: Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits.
Study: NCT02703454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM-guided RF ablation
Study: NCT04007952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Gastropexy
Description: Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
Study: NCT03524391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling based on yoga
Description: Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Usual Care group had standard chemotherapy regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Usual Care group had standard chemotherapy regimens
Study: NCT02403310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5).
Study: NCT01304953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group S+P
Description: In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group S+T
Description: In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
Study: NCT01224509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-treatment
Description: Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
Study: NCT03856424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 1
Description: Pressure support ventilation (PSV) modality
Study: NCT02703454

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional RF ablation
Study: NCT00414986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CQI intervention
Description: In-practice change facilitator assists the practice in implementing a chronic disease registry

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Care Improvement (CCI) Intervention
Description: An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed practice comparison
Description: Practices will have access to all tools used in Arm 1 via a project website
Study: NCT02060240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Activity
Description: The high activity group will undergo a 12 week ramped exercise protocol.
Study: NCT00282425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Allogeneic Hematopoietic stem cell transplantation
Study: NCT04415177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx headset with active intervention
Description: VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EaseVRx headset without active intervention
Description: VR software developed by AppliedVR with neutral non-interactive content.
Study: NCT03006822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release 90
Description: This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release 60
Description: This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release 30
Description: This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
Study: NCT02894645

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Intravenous
Study: NCT03878940

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Abdominal ´yes-no´ pathway
Description: A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
Study: NCT03750136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: high dose furosemide with hypertonic saline 3x daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: high dose furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: high dose furosemide
Study: NCT04635046

Intervention type: PROCEDURE
Intervention: Transfer or extirpation of the peroneus longs tendon
Description: Tendon transfer or extirpation of peroneus longus or brevis tendon, ligamental reconstruction +/- calcaneal osteotomy
Study: NCT01542775

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Group
Description: 12 weeks Aerobic exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: maintaining usual activities
Study: NCT02109055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
Study: NCT03354000

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Take-home online training
Description: We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person online training
Description: For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
Study: NCT04031339

Intervention type: PROCEDURE
Intervention: Standard treatment
Description: e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
Study: NCT02504645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPP-201101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Study: NCT01854554

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMPT
Description: IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
Study: NCT03756207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multidisciplinary bladder-preservation therapy
Description: Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
Study: NCT00424515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
Study: NCT00826176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
Study: NCT00351078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC124
Description: 4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
Study: NCT00795483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic Acid 5mg/year

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Description: Lifestyle modifications

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modifications
Description: Lifestyle modifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Description: Lifestyle modifications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid (5mg/2years)
Study: NCT01336218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: oral tablets, 150mg (3 X 50mg) single dose per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: oral tablets, 150mg (3 X 50mg) single dose per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
Study: NCT00732784

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib mesylate
Description: Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib mesylate
Description: Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: calcium carbonate
Description: Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: calcium carbonate
Description: Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
Study: NCT01933412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac Hepatitis B Vaccine
Description: Sci-B-Vac Hepatitis B Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B Hepatitis B Vaccine
Study: NCT03795064

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foam sclerotherapy
Description: Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Description: Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothermal ablation
Description: Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothermal ablation
Description: Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
Study: NCT00434148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Study: NCT01005407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV and/or Placebo
Description: Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular (IM) injections on Week 0, Week 4 and Week 24
Study: NCT06299631

Intervention type: PROCEDURE
Intervention: Ileocolic resection
Description: Ileocolic resection by open or laparoscopic approach
Study: NCT03739684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging
Description: PET/CT imaging will be acquired 1-2 hours post-PyL injection
Study: NCT01832545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program
Description: Control Group
Study: NCT01139892

Intervention type: PROCEDURE
Intervention: Surgical management

Intervention type: PROCEDURE
Intervention: Endovascular management
Study: NCT00828516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Description: Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
Study: NCT03888092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z650
Description: receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Study: NCT02532023

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3 fatty acid
Description: omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega 3 fatty acid placebo
Description: omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: curcumin placebo
Description: curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months